Table 3 Logistic regression model predicting likelihood of developing major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus without previous history of MACE
Predictor | Males | Females | ||||
|---|---|---|---|---|---|---|
N (%) | Estimate (SE) | OR (95% CI) | N (%) | Estimate (SE) | OR (95% CI) | |
PCSK9 ≥ 244 ng/mL | 105 (47) | −0.376 (0.327) | 0.69 (0.36–1.30) | – | – | – |
PCSK9 ≥ 299 ng/mL | – | – | – | 65 (29) | 0.816 (0.360) | 2.26 (1.12–4.58) |
Current smoking | 36 (16) | −0.122 (0.449) | 0.89 (0.37–2.13) | 34 (15) | 0.425 (0.448) | 1.53 (0.64–3.68) |
Hypertension | 135 (60) | 0.147 (0.340) | 1.16 (0.60–2.25) | 145 (65) | 0.947 (0.369) | 2.58 (1.25–5.31) |
Statin therapy | 29 (13) | 0.477 (0.461) | 1.61 (0.65–3.98) | 45 (20) | −0.070 (0.403) | 0.93 (0.42–2.05) |
Vitamin K antagonist therapy | 19 (8) | 2.197 (0.682) | 8.99 (2.36–34–2) | 21 (9) | 0.239 (0.539) | 1.27 (0.44–3.65) |
Disease duration (years) | 226 | 0.007 (0.015) | 1.01 (0.98–1.04) | 224 | −0.020 (0.018) | 0.98 (0.95–1.01) |
Age (years) | 226 | 0.022 (0.022) | 1.02 (0.98–1.07) | 224 | 0.055 (0.026) | 1.06 (1.01–1.11) |
HbA1c (%) | 226 | 0.125 (0.131) | 1.13 (0.88–1.47) | 224 | 0.229 (0.153) | 1.26 (0.93–1.70) |
hs-CRP (mg/L) | 226 | 0.008 (0.025) | 1.01 (0.96–1.06) | 224 | 0.001 (0.035) | 1.00 (0.93–1.07) |
non-HDL-C (mg/dL) | 226 | 0.006 (0.005) | 1.01 (0.99–1.02) | 224 | −0.003 (0.005) | 1.00 (0.99–1.01) |
BMI (kg/m2) | 226 | −0.029 (0.043) | 0.97 (0.89–1.06) | 224 | −0.010 (0.036) | 0.99 (0.92–1.06) |
eGFR (mL/min) | 226 | 0.013 (0.009) | 1.01 (0.99–1.03) | 224 | −0.013 (0.009) | 0.99 (0.97–1.00) |